[帕博利珠单抗治疗黑色素瘤：最新进展与展望。]

[Pembrolizumab for the treatment of melanoma: updates and perspectives.].

作者信息

Chiarion Sileni Vanna, Mandalà Mario, Queirolo Paola

机构信息

Istituto Oncologico Veneto, Padova.

Ospedale Papa Giovanni XXIII, Bergamo.

出版信息

Recenti Prog Med. 2017 Dec;108(12):528-531. doi: 10.1701/2829.28585.

DOI:10.1701/2829.28585

PMID:29297903

Abstract

Checkpoint inhibitors immunotherapy was a breakthrough in anti-tumor treatments. Anti-PD-1 monoclonal antibodies are now a standard of treatment for advanced melanoma patients, with a 3-year overall survival of over 50% and a low rate (<20%) of severe toxicities in the phase 3 studies. The aim of this review was to report the most important updates on anti-PD-1 drug pembrolizumab from ASCO (American Society of Clinical Oncology) and ESMO (European Society for Medical Oncology) 2017 Annual Meetings.

摘要

检查点抑制剂免疫疗法是抗肿瘤治疗领域的一项突破。抗程序性死亡蛋白1（PD-1）单克隆抗体现已成为晚期黑色素瘤患者的标准治疗方法，在3期研究中，其3年总生存率超过50%，严重毒性发生率较低（<20%）。本综述的目的是报告来自2017年美国临床肿瘤学会（ASCO）和欧洲医学肿瘤学会（ESMO）年会关于抗PD-1药物帕博利珠单抗的最重要更新内容。